



## Practice Profiles Plus

Transforming Cancer Services Team for London

### Selection

Select Area: London NHS region

Select Year: 2015-16

### What is Practice Profiles Plus?

This profile provides a summary of the key diagnosis and referral indicators for your practice or CCG with regards to cancer. The profile enables comparisons to be made with other practices within a CCG, as well as with national figures, to allow for benchmarking and to highlight variations. Each indicator is accompanied by a description of key contextual or influencing factors and provides information on local and/or national resources and initiatives which practices can draw on to help improve cancer outcomes. For raw data methodology and further indicator definitions and

### How should the profile be used?

The purpose of the profile is to help practices reflect on their clinical practice and cancer service delivery, with a particular focus on symptom recognition and early diagnosis. **It is not intended to be a measurement of performance.** However, you may wish to review indicators which are significant outliers for your profile. As many indicators are influenced by factors such as age and deprivation, practices should review this profile in conjunction with their demographic profile. This profile presents crude rates which are not adjusted for demographic factors.

A graph is provided for each indicator to visualise individual practices and how they are performing compared to the CCG, London and England averages. Significance compared to the CCG average is also being shown with colour coding. CCGs can also be visualised comparing how they are performing to the London and England averages. Significance compared to the London average being shown by colour coding. There are five years of historic data available for each indicator as historical data may wish to be reviewed to assess data trends for each indicator over time.

Whilst the data in this tool is presented at the CCG level, individual practices may find it useful to visit the source website to see their individual practice data concisely presented.

Source: <http://fingertips.phe.org.uk/profile/cancerservices>

For further information regarding population size of each practice, and additional variables, for the most recent year please visit

<http://fingertips.phe.org.uk/profile/general-practice/data>

### Contents

Version April 2017

Tab Name	Indicator Title
<a href="#">Exec Summary</a>	Executive Summary
<a href="#">1. 2ww referral ratio</a>	Two-week wait referrals (Indirectly age-sex standardised referral ratio)
<a href="#">2. 2ww conversion</a>	Two-week referrals resulting in a diagnosis of cancer (Conversion rate: % of all 2ww referrals)
<a href="#">3. 2ww detection</a>	Number of new cancer cases treated (Detection rate: % of which resulted from a 2ww referral)
<a href="#">4. 2ww referrals all cancers</a>	Two-week wait referrals for suspected cancer (Number per 100,000 population)
<a href="#">3 &amp; 4. time trend graphs</a>	Time trending for 2ww detection and 2ww referrals for all cancers
<a href="#">5. 2ww referrals breast</a>	Two-week wait referrals for suspected breast cancer (Number per 100,000 population)
<a href="#">6. 2ww referrals lower GI</a>	Two-week wait referrals for suspected lower GI cancers (Number per 100,000 population)
<a href="#">7. 2ww referrals lung</a>	Two-week wait referrals for suspected lung cancer (Number per 100,000 population)
<a href="#">8. 2ww referrals skin</a>	Two-week wait referrals for suspected skin cancer (Number per 100,000 population)
<a href="#">9. screening breast 36 mos</a>	Females, 50-70, screened for breast cancer in last 36 months (3 year coverage, %)
<a href="#">10. screening breast 6 mos</a>	Females, 50-70, screened for breast cancer within 6 months of invitation (Uptake, %)
<a href="#">11. screening cervical</a>	Females, 25-64, attending cervical screening within target period (3.5 or 5.5 year coverage, %)
<a href="#">12. screening bowel 30 mos</a>	Persons, 60-69, screened for bowel cancer in last 30 months (2.5 year coverage, %)
<a href="#">13. screening bowel 6 mos</a>	Persons, 60-69, screened for bowel cancer within 6 months of invitation (Uptake, %)
<a href="#">14. colonoscopy</a>	In-patient or day-case colonoscopy procedures (Number per 100,000 population)
<a href="#">15. sigmoidoscopy</a>	In-patient or day-case sigmoidoscopy procedures (Number per 100,000 population)
<a href="#">16. upper GI endoscopy</a>	In-patient or day-case upper GI endoscopy procedures (Number per 100,000 population)
<a href="#">17. emergency admissions</a>	Number of emergency admissions with cancer (Number per 100,000 population)
<a href="#">18. emergency presentations</a>	Number of emergency presentations (Number per 100,000 population)
<a href="#">19. other presentations</a>	Number of other presentations (Number per 100,000 population)
<a href="#">Detection Rate</a>	Displays yearly detection rates by practice (2010/11 - 2015/16)
<a href="#">Rolling Average Detection Rate</a>	Displays three year rolling averages of detection rates by practice (2010/11 - 2015/16)
<a href="#">Index Table</a>	Displays name and practice code for each GP practice and selected context measures for each practice

Acknowledgments to the Public Health Intelligence Team, Islington for their initial document on which this tool is based.

Acknowledgments to Jason Petit and Chipo Chirewa for their initial work on this tool.

Authored by: Lucy Young, Mary Vu, Molly Loughran, Bethany Wickramasinghe, NCRAS-TCST Partnership.

Area: London NHS region

## Executive Summary

These measures contain some background information about the area population to provide context to the cancer measures. An index is provided at the back of the document containing information for each practice within a chosen CCG.

**Please note that this data is based on varied year formats and ranges due to data availability. For this reason, the year for each indicator must be selected individually.**

### New Cancer Cases

Select Financial Year: 2013-14

Measuring the rate of new cancer cases in each GP and CCG allows for a direct standardised comparison between GPs within a CCG and between CCGs in London. It also allows for comparison between the rates of new cancer cases in a 12 month period. As this is a crude measurement it does not take into account the variation in demographics between GP practices in a CCG, and between CCGs in London, that could affect the rate of new cancer cases including age and deprivation rates (1).

	Area	London	England
New cancer cases (N)	31,707	31,707	290,133
New cancer cases (rate per 100,000 population)	349.8	349.8	515.4
Statistical difference from average	N/A	N/A	N/A

### Quality and Outcomes Framework (QOF) Prevalence

Select Financial Year: 2015-16

General practice has a key role in the referral and subsequent support of these patients and in ensuring that care is appropriately coordinated. Prevalence of cancer has found to be associated with a large range of demographics including age, deprivation and ethnicity. This is an important indicator to provide insight into how many people are currently living with cancer at both CCG and GP level. Variation in cancer prevalence between GPs within a CCG and between CCGs in London may be accounted for by variation in socio-economic characteristics as well as variation in cancer care and treatment.

Extensive work has been carried out by the LWBC Team in TCST to improve the outcomes and quality of life in those living with and beyond cancer (2).

	Area	London	England
QOF prevalent cases (N)	156,310	156,310	1,392,577
QOF prevalence (%)	1.7	1.7	2.4
Statistical difference from average	-	N/A	N/A

### Age (% aged 65+ years)

Select Calendar Year: 2016

The proportion of the population (%) aged 65 years or over is an important demographic to measure as increased age has been identified to be a risk factor in incidence for nearly all cancer types.

It has also been found that those living with cancer (prevalent cases) increase with age, with the two largest age group proportions being 50-64 years and 75+ years (1).

There is an important role for secondary prevention within this patient cohort, including providing support to individuals at risk of recurrence of cancer and new primary cancers.

	Area	London	England
Age (% aged 65+ years)	11.0	11.0	17.2
Statistical difference from average	-	N/A	N/A

### Deprivation score (IMD 2015)

Data only available for: 2015

Deprivation covers a broad range of issues and refers to unmet needs caused by a lack of resources of all kinds, not just financial. The English Indices of Deprivation attempt to measure a broader concept of multiple deprivation, made up of several distinct dimensions, or domains, of deprivation. A score is calculated based on a wide variety of factors thought to contribute to deprivation. The lower the score, the less deprived the area is considered to be.

Research has found that for all major cancers, higher mortality and worse one-year survival are associated with more deprived areas. The only exception being to malignant melanoma, in which higher mortality is associated with the least deprived (2). Note, there is no summary data available for London.

More information can be found at <https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015>.

	Area	London	England
Deprivation score (IMD 2015)	#N/A	N/A	21.8

1. National Cancer Intelligence Network (NCIN), What cancer statistics are available, and where can I find them? (2013).

2. National Cancer Survivorship Initiative Network (NCIN), Living with and beyond cancer: taking action to improve outcomes (2015).


3. National Cancer Intelligence Network (NCIN), Cancer and equality groups: key metrics. (2015).

Area: London NHS region	Year: 2015-16
Two Week Wait Referral Ratio (indirectly age standardised)	
The number of Two Week Wait (2ww) referrals observed at the practice, divided by the number expected based on the practice population age and the age-specific rates for England.	

Although there is no standard rate or number of 2ww referrals, practices should consider how their 2ww referral ratio compares to the England averages, in the context of the socio-demographic profile of the practice population and the underlying incidence of cancer in the local population.

Practices which are significantly above or below the London or England average may wish to review this. Factors to consider are:

- Practices serving very deprived populations with a high prevalence of cancer risk factors, such as smoking, might expect to have higher rates of 2ww referrals.
- Practices serving populations with lower levels of cancer symptom awareness may have lower referral ratios and more cancers diagnosed through emergency presentation.
- Practices should also consider this indicator alongside their conversion rate. A high conversion rate and a low 2ww referral ratio may indicate a high threshold of suspicion of cancer before a 2ww referral is made.




Area: London NHS region	Year: 2015-16		
Two-week referrals resulting in a diagnosis of cancer (Conversion rate: as % of all 2WW referrals)			
The 'conversion rate', i.e., the proportion of Two Week Wait (2ww) referrals resulting in a diagnosis of cancer: the number of 2ww referrals resulting in a diagnosis of cancer in the year, divided by the total number of 2ww referrals in the year.			
A data quality issue has been identified for this indicator/measure: The number of patients per practice is often quite small so variation is inflated by chance considerably. Generally with small sample sizes, process indicators (e.g., rate of 2ww referrals) are considered to be more reliable than outcome indicators, such as this indicator.			
	Area	London	England
Number of cases (N) of 2ww referrals resulting in cancer diagnosis	13,171	13,171	133,016
Average rate (%) 2ww referrals resulting in cancer diagnosis	5.5	5.5	7.8
Expected area cases (N) given regional average	-	13,171	18,679
Statistical significance compared to area	-	N/A	N/A

This indicator, together with the 2ww referral ratio, provides some insight into thresholds of suspicion of cancer within practices before making a 2ww referral, as well as the case-mix of cancers diagnosed in the practice. There is no standard for this indicator. Practices will want to consider how their conversion rate compares to the CCG average, and how the CCG average compares to that of London. Practices which are statistically different to the CCG average, or CCGs which are statistically different to the London average, may wish to review this.

Factors which should be taken into consideration when reviewing this indicator are:

- 2ww referral rate - a high conversion rate could be a reflection of low 2ww referral ratio and a high threshold of suspicion of cancer.
- Cancer case-mix - the conversion rate varies by cancer type so it will depend on the case-mix of cancers in the practice.



Area: London NHS region	Year: 2015-16
Number of new cancer cases treated (Detection rate: % of which resulted from a 2WW referral)	
The proportion of new cancer cases treated who were referred through the Two Week Wait (2ww) referral route. This is calculated as the number of new cancer cases treated in the year who were referred through the 2ww referral route, divided by the total number of patients registered at the practice who have a date of first treatment in the financial year on the Cancer Waiting Times system.	
Please see the Detection Rate Index Table and the Rolling Averages Detection Rate Index Table for detection rates at a practice level for the previous six years.	
A data quality issue has been identified for this indicator/measure: The number of patients per practice is often quite small so variation is inflated by chance considerably. Generally with small sample sizes, process indicators (e.g., rate of 2ww referrals) are considered to be more reliable than outcome indicators, such as this indicator.	


	Area	England
Number new cancer cases (N) diagnosed through 2ww referral	#N/A	136,050
Average proportion (%) of new cancer cases referred by 2ww	#N/A	49.7
Expected area cases (N) given regional average	-	#N/A
Statistical significance compared to area	-	#N/A

This indicator provides a measure of the relative importance of the 2ww pathway compared to other routes to diagnosis. Research indicates that cancers diagnosed via a “managed referral” route have a higher relative survival than cancers diagnosed via an emergency route (1). Although there is no standard for this indicator practices which are statistically different to the CCG average, or CCGs which are statistically different to the London average, may wish to review this. Factors that influence the proportion of cancers diagnosed through this route include thresholds of suspicion of cancer as well as patient awareness and delays in presentation. Practices can be encouraged to undertake audit of all cancer diagnoses and discuss route to diagnosis at clinical meetings to identify local trends and approached to cancer diagnosis.

#### Several resources are available to aid practices in making 2ww referrals:

- NICE referral guidelines for suspected cancer (<https://www.nice.org.uk/guidance/ng12>)
- Risk assessment tools for bowel, lung, prostate, ovarian and pancreatic cancers (2014)- (available at: [www.qcancer.org](http://www.qcancer.org))
- Referral forms (available at: <https://www.myhealth.london.nhs.uk/healthy-london/suspected-cancer-referrals>).
- BMJ Learning—Carcinoma of unknown primary origin: diagnosis and management: putting NICE guidelines into practice (last updated 2010) (<http://learning.bmj.com/learning/module-intro/.html?moduleId=10017700>)
- Practices may also wish to consider if they can do more to promote awareness of cancer symptoms and encourage earlier presentation amongst their registered population.

1. National Cancer Intelligence Network (NCIN), Routes to Diagnosis: Exploring Emergency Presentations (2013), [http://www.ncin.org.uk/publications/data\\_briefings/routes\\_to\\_diagnosis\\_exploring\\_emergency\\_presentations](http://www.ncin.org.uk/publications/data_briefings/routes_to_diagnosis_exploring_emergency_presentations)



Area: London NHS region	Year: 2015-16		
Two-week wait referrals for suspected cancer (Number per 100,000 population)			
The crude rate of referrals per 100,000 persons: the number of Two Week Wait (2ww) referrals for suspected cancer (multiplied by 100,000), divided by the list size of the practice in question.			
	Area	London	England
Number (N)	238,678	238,678	1,711,263
Rate per 100,000 population	2,538.9	2,538.9	2,975.1
Statistical difference from average	-	N/A	N/A

This indicator provides some insight into the thresholds of suspicion of cancer within both practices and CCGs. This information may also provide insight into health seeking behaviours within the region. This data can be used to compare the number of cancer cases at CCG level that were presented through different routes of diagnosis with those diagnosed through 2ww referral.

Although there is no standard rate or number of 2ww referrals, CCGs and practices should consider how their 2ww referral rate compares to the London and England averages, in the context of the socio-demographic profile of the practice population and the underlying incidence of cancer in the local population.


Practices which are statistically different to the CCG average, or CCGs which are statistically different to the London average, may wish to review this. Factors to consider are:

- Practices serving very deprived populations with a high prevalence of cancer risk factors, such as smoking, might expect to have higher rates of 2ww referrals.
- Practices serving populations with lower levels of cancer symptom awareness may have lower referral rates and more cancers diagnosed through emergency presentation.
- Practices should also consider this indicator alongside their conversion rate. For example, a high 2ww referral rate with a high conversion rate would be preferable to a high referral rate and a low conversion rate. A high conversion rate and a low 2ww referral rate may indicate a high threshold of suspicion of cancer before a 2ww referral is made.

**Several resources are available to aid practices in making 2ww referrals for suspected cancer:**

- NICE referral guidelines for suspected cancer ([www.nice.org.uk/guidance/ng12](http://www.nice.org.uk/guidance/ng12))
- Referral forms for cancer (available at: <https://www.myhealth.london.nhs.uk/healthy-london/suspected-cancer-referrals>).

Area Comparison of Two Week Wait Referrals for Suspected Cancer




Area:	London NHS region
-------	-------------------

**Trend Over Time for Proportion of New Cancer Cases Treated by Two Week Wait Referral**


Please note no comparison data are available against the London NHS region average.

Year	Area	England
2010-11	#N/A	43.7
2011-12	#N/A	45.0
2012-13	#N/A	46.3
2013-14	#N/A	47.4
2014-15	#N/A	48.4
2015-16	#N/A	49.7



**Trend Over Time for Two Week Wait Referrals for Suspected Cancer**

Year	Area	London	England
2010-11	1372.8	1372.8	1808.3
2011-12	1491.9	1491.9	1977.7
2012-13	1689.7	1689.7	2165.0
2013-14	1931.6	1931.6	2396.6
2014-15	2260.0	2260	2707.7
2015-16	2538.9	2538.9	2975.1



Area: London NHS region	Year: 2015-16		
Two-week wait referrals for suspected breast cancer (Number per 100,000 population)			
The crude rate of referrals per 100,000 persons: the number of Two Week Wait (2ww) referrals for suspected breast cancer (multiplied by 100,000), divided by the list size of the practice in question.			
	Area	London	England
Number (N)	45,557	45,557	311,224
Rate per 100,000 population	484.6	484.6	541.1
Statistical difference from average	-	N/A	N/A


Although there is no national standard for this indicator practices which are statistically different to the CCG average, or CCGs which are statistically different to the London average, may wish to review this. Factors to consider are:

- Practices with a high proportion of patients over 65 years may expect a higher 2ww referral rate due to the higher incidence of breast cancer in older women.
- Practices serving populations with lower levels of breast cancer symptom awareness may have a lower referral rate and more cancers diagnosed through emergency presentation.

Several resources are available to aid practices in making 2ww referrals for suspected breast cancer:

- NICE referral guidelines for suspected cancer ([www.nice.org.uk/guidance/ng12](http://www.nice.org.uk/guidance/ng12))
- NICE guidance on familial breast cancer (<https://www.nice.org.uk/guidance/CG164>)
- BMJ Learning 'Suspected breast cancer: when you should refer' (<http://learning.bmj.com/learning/module-intro/.html?moduleId=5003318>) (module ID - 5003318)
- Referral forms for breast cancer (available at: <https://www.myhealth.london.nhs.uk/healthy-london/suspected-cancer-referrals>).

#### Area Comparison of Two Week Wait Referrals for Suspected Breast Cancer





<b>Area:</b> London NHS region	<b>Year:</b> 2015-16
<b>Two-week wait referrals for suspected lower GI cancers</b> (Number per 100,000 population)	
The crude rate of referrals per 100,000 persons: the number of Two Week Wait (2ww) referrals for suspected lower gastrointestinal (GI) cancer (multiplied by 100,000), divided by the list size of the practice in question.	

	Area	London	England
Number (N)	34,149	34,149	260,713
Rate per 100,000 population	363.2	363.2	453.3
Statistical difference from average	-	N/A	N/A


Although there is no national standard for this indicator practices which are statistically different to the CCG average, or CCGs which are statistically different to the London average, may wish to review this. Factors to consider are:

- Practices with a high proportion of patients over 65 years may expect a higher 2ww referral rate due to the increasing incidence of lower GI cancer with age.
- Practices serving populations with lower levels of cancer symptom awareness may have a lower referral rate and more cancers diagnosed through emergency presentation.

**Several resources are available to aid practices in making 2ww referrals for suspected lower GI cancer:**

- Symptom checker tool for bowel cancer - (available at: <http://www.nhs.uk/Tools/Pages/Bowel-cancer-self-assessment.aspx>)
- Small c bowel campaign (available at: <http://www.smallc.org.uk/bowel/>)
- BMJ Learning <http://learning.bmj.com/learning/module-intro/cancer-referral.html?moduleid=10053492> — module on 'Quick tips: referral for suspected cancer' (module ID - 10053492)
- Referral forms for lower GI and colorectal cancers (available at: <https://www.myhealth.london.nhs.uk/healthy-london/suspected-cancer-referrals>).

**Area Comparison of Two Week Wait Referrals for Suspected Lower GI Cancer**



Area: London NHS region	Year: 2015-16
Two-week wait referrals for suspected lung cancer (Number per 100,000 population)	
The crude rate of referrals per 100,000 persons: the number of Two Week Wait (2ww) referrals for suspected lung cancer (multiplied by 100,000), then divided by the list size of the practice in question.	

	Area	London	England
Number (N)	9,266	9,266	59,443
Rate per 100,000 population	98.6	98.6	103.3
Statistical difference from average	-	N/A	N/A


Although there is no national standard for this indicator practices which are statistically different to the CCG average, or CCGs which are statistically different to the London average, may wish to review this. Factors to consider are:

- Practices with a high proportion of patients over 65 years may expect a higher 2ww referral rate due to the increasing incidence of lung cancer with age.
- Practices serving populations with a high smoking prevalence may expect to have a higher rate of 2ww referrals.
- Practices serving populations with lower levels of lung cancer symptom awareness may have a lower referral rate and more cancers diagnosed through emergency presentation.

#### Several resources are available to aid practices in making 2ww referrals for suspected lung cancer:

- Referral forms for lung cancer - (available at: <https://www.myhealth.london.nhs.uk/healthy-london/suspected-cancer-referrals>).
- Risk assessment tools for lung cancer (smokers and non-smokers) - (available at: <http://www.cancerresearchuk.org/health-professional/early-diagnosis-activities/national-awareness-and-early-diagnosis-initiative-naedi>)
- Cancer Research UK's Lung cancer campaign: Information for GPs - provides guidance and tips for referrers (<http://www.cancerresearchuk.org/health-professional/early-diagnosis-activities/be-clear-on-cancer/lung-cancer-campaign/information-for-gps>)
- NHS's Clear on Cancer campaign on lung cancer symptoms (<http://www.nhs.uk/be-clear-on-cancer/lung-cancer/symptoms>)
- NICE guidelines for lung cancer (2015) <https://cks.nice.org.uk/lung-and-pleural-cancers-recognition-and-referral#topicsummary>

#### Area Comparison of Two Week Wait Referrals for Suspected Lung Cancer



<b>Area:</b> London NHS region	<b>Year:</b> 2015-16
<b>Two-week wait referrals for suspected skin cancer (Number per 100,000 population)</b>	
The crude rate of referrals per 100,000 persons: the number of Two Week Wait (2ww) referrals for suspected skin cancer (multiplied by 100,000), divided by the list size of the practice in question.	

	Area	London	England
Number (N)	45,349	45,349	328,871
Rate per 100,000 population	482.4	482.4	571.8
Statistical difference from average	-	N/A	N/A


Although there is no national standard for this indicator practices which are statistically different to the CCG average, or CCGs which are statistically different to the London average, may wish to review this. Factors to consider are:

- Practices with a high proportion of patients over 65 years may expect a higher 2ww referral rate due to the higher incidence of skin cancer in this age range.
- Practices serving populations with lower levels of skin cancer symptom awareness may have a lower referral rate and more cancers diagnosed through emergency presentation.

**Several resources are available to aid practices in making 2ww referrals for suspected skin cancer:**

- NICE referral guidelines for suspected cancer (<http://cks.nice.org.uk/skin-cancers-recognition-and-referral#!topicsummary>)
- Referral forms for skin cancer (available at: <https://www.myhealth.london.nhs.uk/healthy-london/suspected-cancer-referrals>).
- Pan-London Suspected Skin Cancer Referral Guide (<https://www.myhealth.london.nhs.uk/nhsrefer/formlinks/guides/Pan%20London%20Suspected%20Cancer%20Referral%20Guide%20Skin.pdf>)
- Doctors.net Skin Cancer Toolkit ([http://www.doctors.net.uk/eclient/cruk/cruk\\_skin\\_toolkit\\_2014/](http://www.doctors.net.uk/eclient/cruk/cruk_skin_toolkit_2014/))
- BMJ Learning--Basal cell carcinoma: diagnosis and treatment (archived) (<http://learning.bmj.com/learning/module-intro/basal-cell-carcinoma-diagnosis-treatment.html?moduleId=5003142>)
- BMJ Learning--Malignant melanomas: diagnosis and management (<http://learning.bmj.com/learning/module-intro/malignant-melanomas-diagnosis-management.html?moduleId=5003313>) (archived)

**Area Comparison of Two Week Wait Referrals for Suspected Skin Cancer**



Area:	London NHS region	Year:	2015-16
Females, 50-70, screened for breast cancer in last 36 months (3 year coverage, %)			
Three-year screening coverage (%): The number of females registered to the practice who were adequately screened in previous 36 months, divided by the number of eligible females on last day of the review period.			
70% National minimum standard for all Breast Cancer screening			
	Area	London	England
Number cases (N)	582,761	582,761	5,044,802
% eligible population screened	65.1	65.1	72.5
Difference from 70% national minimum standard (%)	-4.9	-4.9	2.5
Statistical significance compared to area	-	N/A	N/A

Breast cancer screening is an important intervention for detecting breast cancer early. Screening saves about one life from breast cancer for every 200 women who are screened. This adds up to about 1,300 lives saved from breast cancer by screening each year in the UK (1).

Inequalities exist in screening uptake with certain groups being less likely to attend, including:

- women in the 50-54 age group
- BME groups and Muslim women
- women from a more deprived background

**The following initiatives can help improve breast cancer screening coverage and reduce inequalities:**

- List maintenance - ensure patient records are accurate and up-to-date, including addresses and telephone numbers.
- Follow-up with women who did not attend their screening appointment. Evidence shows positive endorsement from a healthcare professional can increase screening uptake (2).
- Use reminder flags on patient records for women who have missed their screening appointment to prompt a discussion with the patient regarding breast screening.

- For more information regarding screening:

<https://www.myhealth.london.nhs.uk/healthy-london/cancer-resources>


- Make use of easy read leaflets for women with learning disabilities.

<https://www.gov.uk/government/publications/breast-screening-information-for-women-with-learning-disabilities>

1. Source: NHS, NHS Breast Screening: Helping you decide (2013)

2. Hewitson, P., Ward, A., Heneghan, C., Halloran, S. & Mant, D. (2011) Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial

**Area Comparison of Females, 50-70, Screened for Breast Cancer in Last 36 Months (3 Year Coverage, %)**



Area: London NHS region	Year: 2015-16		
Females, 50-70, screened for breast cancer within 6 months of invitation (Uptake, %)			
One-year screening uptake (%): the number of females registered to the practice aged 50-70 invited for screening in the previous 12 months who were screened within 6 months of invitation, divided by the total number of females aged 50-70 invited for screening in the previous 12 months.			
70% National minimum standard for all Breast Cancer screening			
	Area	London	England
Number cases (N)	200,519	200,519	1,790,555
% eligible population screened	67.1	67.1	73.5
Difference from 70% national minimum standard (%)	-2.9	-2.9	3.5
Statistical significance compared to area	-	N/A	N/A

The proportion of women who are screened within 6 months of invitation is an important metric to measure as it has been found that those that attend screening earlier are often associated with improved survival and better prognosis.

Breast cancer screening is an important intervention for early detection of breast cancers. Screening saves about one life from breast cancer for every 200 women who are screened (1). This adds up to about 1,300 lives saved from breast cancer by screening each year in the UK.

Inequalities exist in screening uptake with certain groups being less likely to attend, including:

- women in the 50-54 age group
- BME groups and Muslim women
- women from a more deprived background

**The following initiatives can help improve time to breast cancer screening coverage and reduce inequalities:**


- List maintenance - ensure patient records are accurate and up-to-date, including addresses and telephone numbers.
- Follow-up with women who did not attend their screening appointment. Evidence shows positive endorsement from a healthcare professional can increase screening uptake (2).
- Use reminder flags on patient records for women who have missed their screening appointment to prompt a discussion with the patient regarding breast screening.

• For more information regarding screening:  
<https://www.myhealth.london.nhs.uk/healthy-london/cancer-resources>

• Make use of easy read leaflets for women with learning disabilities.  
<https://www.gov.uk/government/publications/breast-screening-information-for-women-with-learning-disabilities>

1. Source: NHS, NHS Breast Screening: Helping you decide (2013)

2. Hewitson, P., Ward, A., Heneghan, C., Halloran, S. & Mant, D. (2011) Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial



Area:	London NHS region	Year:	2015-16
Females, 25-64, attending cervical screening within target period (3.5 or 5.5 year coverage, %)			
The overall cervical screening coverage (%): the number of women registered at the practice who were adequately screened in the previous 42 months (if aged 24-49) or 66 months (if aged 50-64), divided by the number of eligible women on last day of review period.			
80% National minimum standard for Cervical Cancer screening coverage			
	Area	London	England
Number cases (N)	1,778,802	1,778,802	10,441,361
% eligible population screened	66.8	66.8	72.8
Difference from 80% national minimum standard (%)	-13.2	-13.2	-7.2
Statistical significance compared to area	-	N/A	N/A

Cervical cancer screening reduces the incidence of cervical cancer. Evidence suggests that screening was associated with a 60% reduction of cancers in women aged 40, and an 80% reduction in those aged 64 years (1). Screening was also found to be particularly effective in preventing advanced stage cancers.

Inequalities exist in screening uptake with certain groups being less likely to attend, including:

- women in the 25-34 year age group
- BME groups
- women from a more deprived background

**The following initiatives can help improve cervical cancer screening coverage and reduce inequalities:**

- List maintenance - ensure patient records are accurate and up-to-date, including addresses and telephone numbers.
- Follow-up with women who did not attend their screening appointment. Evidence shows positive endorsement from a healthcare professional can increase screening uptake (2).
- Use reminder flags on patient records for women who have missed their screening appointment to prompt a discussion with the patient regarding cervical screening.
- Ensure women have access to cervical screening at times and locations that are convenient to them.

- For more information regarding screening:


<https://www.myhealth.london.nhs.uk/healthy-london/cancer-resources>

- Make use of easy read leaflets for people with learning disabilities

<https://www.gov.uk/government/publications/cervical-screening-easy-read-guide>

1. Sasieni, P., Castanon, A. and Cuzick, J., 2009. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. *BMJ*, 339, p.b2968.

2. Hewitson, P., Ward, A., Heneghan, C., Halloran, S. & Mant, D. (2011) Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial



Area: London NHS region	Year: 2015-16
Persons, 60-69, screened for bowel cancer in last 30 months (2.5 year coverage, %)	
2.5-year screening coverage (%): The number of persons registered to the practice who were adequately screened in the previous 30 months, divided by the number of eligible persons on last day of the review period.	

60% National minimum standard for overall Bowel screening coverage			
	Area	London	England
Number cases (N)	335,600	335,600	3,494,269
% eligible population screened	48.8	48.8	57.8
Difference from 60% national minimum standard (%)	-11.2	-11.2	-2.2
Statistical significance compared to area	-	N/A	N/A

Bowel cancer screening can reduce deaths from bowel cancer by up to 15% (1). Inequalities exist in screening uptake with certain groups being less likely to attend, including:

- BME groups and Muslim men and women
- people from a more deprived background
- men and women aged 60-65 years

**The following initiatives can help improve bowel cancer screening coverage and reduce inequalities:**

- List maintenance - ensure patient records are accurate and up-to-date, including addresses and telephone numbers.
- Follow-up patients who did not return their screening kit. Evidence shows positive endorsement from a healthcare professional can increase screening uptake (2).
- Use reminder flags on patient records for those who did not attend

- For more information regarding screening:


<https://www.myhealth.london.nhs.uk/healthy-london/cancer-resources>

- Make use of easy read leaflets for people with learning disabilities

<https://www.gov.uk/government/collections/bowel-cancer-screening-commission-provide-inform>

1. Hewitson P, Glaziou P, Towler B, et al. (2011). Screening for colorectal cancer using the faecal occult blood test: an update. The Cochrane Database of Systematic Reviews. [Online].

2. Hewitson, P., Ward, A., Heneghan, C., Halloran, S. & Mant, D. (2011) Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial



<b>Area:</b> London NHS region	<b>Year:</b> 2015-16
<b>Persons, 60-69, screened for bowel cancer within 6 months of invitation (Uptake, %)</b>	
Screening uptake (%): the number of persons aged 60-69 invited for screening in the previous 12 months who were adequately screened following an initial response within 6 months of invitation, divided by the total number of persons aged 60-69 invited for screening in the previous 12 months.	

**60% National minimum standard for overall Bowel screening coverage**

	Area	London	England
<b>Number cases (N)</b>	159,968	159,968	1,682,289
<b>% Eligible population screened</b>	45.6	45.6	55.6
<b>Difference from 60% national minimum standard (%)</b>	-14.4	-14.4	-4.4
<b>Statistical significance compared to area</b>	-	N/A	N/A

Bowel cancer screening can reduce deaths from bowel cancer by up to 15% (1). Inequalities exist in screening uptake with certain groups being less likely to attend, including:

- BME groups and Muslim men and women
- people from a more deprived background
- men and women aged 60-65 years

**The following initiatives can help improve bowel cancer screening coverage and reduce inequalities:**

- List maintenance - ensure patient records are accurate and up-to-date, including addresses and telephone numbers.
- Follow-up with patients who did not return their screening kit. Evidence shows positive endorsement from a healthcare professional can increase screening uptake (2).
- Use reminder flags on patient records for those who did not attend screening.

- For more information regarding screening:


<https://www.myhealth.london.nhs.uk/healthy-london/cancer-resources>

- Make use of easy read leaflets for people with learning disabilities

<https://www.gov.uk/government/publications/bowel-cancer-screening-easy-guide>.

1. Hewitson P, Glaziosi P, Towler B, et al. (2011). Screening for colorectal cancer using the faecal occult blood test: an update. The Cochrane Database of Systematic Reviews. [Online].

2. Hewitson, P., Ward, A., Heneghan, C., Halloran, S. & Mant, D. (2011) Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial





Area: London NHS region Year: 2015-16

# In-patient or day-case colonoscopy procedures (Number per 100,000 population)

The crude rate per 100,000 persons of colonoscopies performed on persons registered at the practice: the number of colonoscopies (in-patient and day-case) multiplied by 100,000, divided by the list size of the practice in question.

These procedures were not filtered by the diagnostic field in the HES data so contain both patients subsequently diagnosed with cancer, those not subsequently diagnosed with cancer, and patients where there was no suspicion of cancer. Further, this includes procedure data for both primary and secondary care referrals. Procedures with Office of Population Census and Surveys Classification of Surgical Operations and Procedures (4th revision) (OPCS-4) 3-digit codes of H22 are included.


	Area	London	England
Number (N)	61,183	61,183	421,690
Colonoscopies performed (per 100,000 population)	650.7	650.7	733.1
Statistical difference from average	-	N/A	N/A

Despite the rate of colonoscopy procedures also including those for which there is no suspicion of cancer, it is considered that the majority of colonoscopy procedures will be used for investigation of cancer. Comparing the number of colonoscopies between GPs within a CCG and comparing different CCGs to the London and England averages is important because it provides possible insight into the number of investigations for bowel and colorectal cancer.

Several resources are available to provide further information on the colonoscopy procedure and colorectal cancer testing:

- Cancer Research UK's guide to Bowel Cancer Tests (<http://www.cancerresearchuk.org/about-cancer/type/bowel-cancer/diagnosis/bowel-cancer-tests#colonoscopy>).
- NHS Choice's guide to Diagnosing bowel cancer (<http://www.nhs.uk/Conditions/Cancer-of-the-colon-rectum-or-bowel/Pages/Diagnosis.aspx>).
- The BMJ's guide to Colorectal screening for older adults (<http://www.bmj.com/content/350/bmj.h2029>).

## Area Comparison of In-Patient or Day-Case Colonoscopy Procedures (Number per 100,000 Population)



Area: London NHS region	Year: 2015-16
<b>In-patient or day-case sigmoidoscopy procedures (Number per 100,000 population)</b>	
The crude rate per 100,000 persons of sigmoidoscopies performed on persons registered at the practice: the number of sigmoidoscopies (in-patient and day-case) multiplied by 100,000, divided by the list size of the practice in question.	


These procedures were not filtered by the diagnostic field in the HES data so contain both patients subsequently diagnosed with cancer, those not subsequently diagnosed with cancer, and patients where there was no suspicion of cancer. Further, this includes procedure data for both primary and secondary care referrals. Procedures with Office of Population Census and Surveys Classification of Surgical Operations and Procedures (4th revision) (OPCS-4) 3-digit codes of H25 or H28 are included.

	Area	London	England
Number (N)	34,829	34,829	274,734
Sigmoidoscopies performed (per 100,000 population)	370.4	370.4	477.6
Statistical difference from average	-	N/A	N/A

Despite the rate of sigmoidoscopy procedures also including those for which there is no suspicion of cancer, it is considered that the majority of sigmoidoscopy procedures will be used for investigation of cancer. Comparing the number of sigmoidoscopies between GPs within a CCG and comparing different CCGs to the London and England averages is important because it provides possible insight into the number of investigations for bowel cancer.

Several resources are available to provide further information on the sigmoidoscopy procedure and bowel cancer testing:

- Cancer Research UK's guide to bowel cancer tests (<http://www.cancerresearchuk.org/about-cancer/type/bowel-cancer/diagnosis/bowel-cancer-tests#colonoscopy>)
- NHS Choice's guide to diagnosing bowel cancer (<http://www.nhs.uk/Conditions/Cancer-of-the-colon-rectum-or-bowel/Pages/Diagnosis.aspx>).
- The BMJ's guide to sigmoidoscopy screening for colorectal cancer (<http://www.bmj.com/content/338/bmj.b2084>).



Area: London NHS region	Year: 2015-16
<b>In-patient or day-case upper GI endoscopy procedures (Number per 100,000 population)</b>	
The crude rate per 100,000 persons of endoscopies of the upper gastrointestinal tract performed on persons registered at the practice: the number of endoscopies of the upper gastrointestinal tract (in-patient and day-case) multiplied by 100,000, divided by the list size of the practice in question.	

These procedures were not filtered by the diagnostic field in the HES data so contain both patients subsequently diagnosed with cancer, those not subsequently diagnosed with cancer, and patients where there was no suspicion of cancer. Further, this includes procedure data for both primary and secondary care referrals. Procedures with Office of Population Census and Surveys Classification of Surgical Operations and Procedures (4th revision) (OPCS-4) 3-digit codes of G16 and G45 are included.


	Area	London	England
Number (N)	104,161	104,161	749,164
Upper GI endoscopies performed (per 100,000 population)	1107.9	1107.9	1302.4
Statistical difference from average	-	N/A	N/A

Despite the rate of upper GI endoscopy procedures also including those for which there is no suspicion of cancer, it is considered that the majority of upper GI procedures will be used for investigation of cancer. Comparing the number of upper GI endoscopies between GPs within a CCG and comparing different CCGs to the London and England averages is important because it provides possible insight into the number of investigations for stomach cancer.

Several resources are available to provide further information on the upper GI endoscopy procedure and stomach cancer testing:

- Cancer Research UK's guide to Endoscopy (<http://www.cancerresearchuk.org/about-cancer/cancers-in-general/tests/endoscopy>).
- NHS Choices' guide to Endoscopy (<http://www.nhs.uk/conditions/Endoscopy/Pages/Introduction.aspx>).

### Area Comparison of In-Patient or Day-Case Upper GI Endoscopy Procedures (Number per 100,000 population)



<b>Area:</b>	London NHS region	<b>Year:</b>	2015-16
<b>Number of emergency admissions with cancer (Number per 100,000 population)</b>			
The crude rate per 100,000 persons of all emergency admissions with an invasive, in-situ, uncertain or unknown behaviour, or benign brain cancer (ICD-10 C00-C97, D00-D09, D33, and D37-48), present in any of the first three diagnostic fields (HES inpatient database) per patients on the practice register.			
A data quality issue has been identified for this indicator/measure: The number of patients per practice is often quite small so variation is inflated by chance considerably. Generally with small sample sizes, process indicators (e.g., rate of 2ww referrals) are considered to be more reliable than outcome indicators, such as this indicator.			

	Area	London	England
<b>Number (N)</b>	39,260	39,260	308,950
<b>Rate per 100,000 population</b>	418.3	418.3	537.8
<b>Area statistical difference from average</b>	-	N/A	N/A

Certain cancers are more likely to be diagnosed through an emergency route, with over half (62%) of central nervous system (CNS) cancers in England diagnosed via all emergency routes, as are 39% of lung cancers - the third most common cancer in England. One year relative survival for cancers diagnosed through emergency presentation is significantly lower than all other routes to diagnosis (1). This data is intended to provide an insight into patients' routes to diagnosis to CCGs and to encourage practices to consider how their own patients present with cancer.

Note: Emergency routes include A&E, GP emergency referral, in-patient emergency admission, or other out-patient emergency referral (2).

Further, it has been found that age, sex, deprivation, and tumour site also effect the method of presentation and is something that should be considered (3).


Practices may wish to carry out an audit and/or significant event analysis (SEA) on patients diagnosed through an emergency route, to identify whether any practice level improvements could be made.

The following resources are available to aid practices in undertaking audits and SEAs:

- Royal College of GPs audit template and guidance (available at: <http://www.rcgp.org.uk/clinical-and-research/our-programmes/quality-improvement/significant-event-audit.aspx>)

1. Routes to Diagnosis: Exploring Emergency Presentations (2013), [http://www.ncin.org.uk/publications/data\\_briefings/routes\\_to\\_diagnosis\\_exploring\\_emergency\\_presentations](http://www.ncin.org.uk/publications/data_briefings/routes_to_diagnosis_exploring_emergency_presentations)
2. Hospital Episodes Survey (HES) Data Dictionary (2015). <http://www.hscic.gov.uk/hesdatadictionary>
3. Abel, G. A., et al. Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers. British Journal of Cancer; 112 (2015): S129-S136.

### Area Comparison of Number of Emergency Admissions with Cancer (Number per 100,000 Population)



Area:	London NHS region	Year:	2015-16
Number of emergency presentations (Number per 100,000 population)			
The crude rate of persons diagnosed with cancer via an emergency route, divided by the number of persons in the practice list, expressed as a rate per 100,000 population.			
A data quality issue has been identified for this indicator/measure: The number of patients per practice is often quite small so variation is inflated by chance considerably. Generally with small sample sizes, process indicators (e.g., rate of 2ww referrals) are considered to be more reliable than outcome indicators, such as this indicator.			
	Area	London	England
Number (N)	6,090	6,090	51,164
Rate per 100,000 population	64.8	64.8	88.9
Area statistical difference from average	-	N/A	N/A

Certain cancers are more likely to be diagnosed through an emergency route, with over half (62%) of central nervous system (CNS) cancers in England diagnosed via an emergency route, as are 39% of lung cancers - the third most common cancer in England. One year relative survival for cancers diagnosed through emergency presentation is significantly lower than all other routes to diagnosis (1). This data is intended to provide an insight into patients' routes to diagnosis and to encourage practices and CCGs to consider how their own patients present with cancer.

It is important to ascertain what proportion of new cancer cases are diagnosed by emergency route compared to other methods of diagnosis.

Possible reasons for emergency presentation are as follows:

- a person was diagnosed through an emergency route due to not attending a screening appointment
- symptoms had previously been missed by a GP
- severity of symptoms

Note: Emergency routes include A&E, GP emergency referral, in-patient emergency admission, or other out-patient emergency referral (2).

Further, it has been found that age, sex, deprivation, and tumour site also effect the method of presentation and is something that should be considered (3).

Practices may wish to carry out an audit and/or significant event analysis (SEA) on patients diagnosed through an emergency route, to identify whether any practice level improvements could be made.

The following resources are available to aid practices in undertaking audits and SEAs:

- Royal College of GPs audit template and guidance (available at: <http://www.rcgp.org.uk/clinical-and-research/our-programmes/quality-improvement/significant-event-audit.aspx>)


1. Routes to Diagnosis: Exploring Emergency Presentations (2013),

[http://www.ncin.org.uk/publications/data\\_briefings/routes\\_to\\_diagnosis\\_exploring\\_emergency\\_presentations](http://www.ncin.org.uk/publications/data_briefings/routes_to_diagnosis_exploring_emergency_presentations)

2. Hospital Episodes Survey (HES) Data Dictionary (2015). <http://www.hscic.gov.uk/hesdatadictionary>

3. Abel, G. A., et al. Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers. British Journal of Cancer; 112 (2015): S129-S136.

Area Comparison of Number of Emergency Presentations  
(Number per 100,000 population)



<b>Area:</b> London NHS region	<b>Year:</b> 2015-16
<b>Number of other presentations (Number per 100,000 population)</b>	
The crude rate of persons diagnosed with cancer via a non-emergency route, divided by the number of persons in the practice list, expressed as a rate per 100,000 persons.	
A data quality issue has been identified for this indicator/measure: The number of patients per practice is often quite small so variation is inflated by chance considerably. Generally with small sample sizes, process indicators (e.g., rate of 2ww referrals) are considered to be more reliable than outcome indicators, such as this indicator.	

	Area	London	England
<b>Number (N)</b>	23,561	23,561	207,881
<b>Rate per 100,000 population</b>	250.6	250.6	361.4
<b>Area statistical difference from average</b>	-	N/A	N/A

Certain cancers are more likely to be diagnosed through an emergency route, with over half (62%) of central nervous system (CNS) cancers in England diagnosed via an emergency route, as are 39% of lung cancers - the third most common cancer in England. One year relative survival for cancers diagnosed through emergency presentation is significantly lower than all other routes to diagnosis (1). This data is intended to provide an insight into patients' routes to diagnosis and to encourage practices and CCGs to consider how their own patients present with cancer. Possible non-emergency routes to diagnosis include: screen detected, 2ww, GP referral, in-patient elective, and other non-emergency presentations (2). Further, it has been found that age, sex, deprivation, and tumour site also effect the method of presentation and is something that should be considered (3).

Practices may wish to carry out an audit and/or significant event analysis (SEA) on patients diagnosed through an emergency route (this metric is looking at non-emergency), to identify whether any practice level improvements could be made.

The following resources are available to aid practices in undertaking audits and SEAs:


- Royal College of GPs audit template and guidance (available at: <http://www.rcgp.org.uk/clinical-and-research/our-programmes/quality-improvement/significant-event-audit.aspx>)

1. Routes to Diagnosis: Exploring Emergency Presentations (2013), [http://www.ncin.org.uk/publications/data\\_briefings/routes\\_to\\_diagnosis\\_exploring\\_emergency\\_presentations](http://www.ncin.org.uk/publications/data_briefings/routes_to_diagnosis_exploring_emergency_presentations)

2. Hospital Episodes Survey (HES) Data Dictionary (2015). <http://www.hscic.gov.uk/hesdatadictionary>

3. Abel, G. A., et al. Cancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancers. British Journal of Cancer; 112 (2015): S129-S136.

**Area Comparison of Number of Other Presentations  
(Number per 100,000 population)**



## Detection Rates Index Table

**Note: This table is not available at the London level**

Source: <http://fingertips.phe.org.uk/profile/cancerservices>

**Area:** London NHS region

Detection rate is the proportion of cancers detected via the 2 week wait pathway compared to the total number of cancers in that practice. This route is the preferred pathway to ensure rapid access to tests and treatments. Typically, it is around 45-50% in London. However, there is year on year variation in this figure at practice level and at CCG level. Practices demonstrating greater than expected variation in their data can seek reasons for this (sometimes relating to clinical practice or practice systems). In order to take into account natural, expected variation, data from multiple years has been tabulated.

Low numbers of suspected cancer cases at a practice level can lead to large fluctuation in the detection rates. To account for this, three-year rolling averages have been calculated.

Practice Code	Practice Name	2010-11	2011-12	2012-13	2013-14	2014-15	2015-16	Average
	England	43.7	45	46.3	47.4	48.4	49.7	46.75
	London NHS region							

## Detection Rates Index Table

**Note: This table is not available at the London level**

Source: <http://fingertips.phe.org.uk/profile/cancerservices>

**Area:** London NHS region

Detection rate is the proportion of cancers detected via the 2 week wait pathway compared to the total number of cancers in that practice. This route is the preferred pathway to ensure rapid access to tests and treatments. Typically, it is around 45-50% in London. However, there is year on year variation in this figure at practice level and at CCG level. Practices demonstrating greater than expected variation in their data can seek reasons for this (sometimes relating to clinical practice or practice systems). In order to take into account natural, expected variation, data from multiple years has been tabulated.

Low numbers of suspected cancer cases at a practice level can lead to large fluctuation in the detection rates. To account for this, three-year rolling averages have been calculated.

Practice Code	Practice Name	2010-11	2011-12	2012-13	2013-14	2014-15	2015-16	Average
---------------	---------------	---------	---------	---------	---------	---------	---------	---------



## Rolling Averages Detection Rates Index Table

**Note: This table is not available at the London level**

Source: <http://fingertips.phe.org.uk/profile/cancerservices>

**Area:** London NHS region

Three-year rolling average detection rates have been presented at a practice level for a selected CCG, along with the average detection rate over the six years.

Low numbers of suspected cancer cases at a practice level can lead to large fluctuation in the detection rates. To account for this, three-year rolling averages have been calculated.

Practice Code	Practice Name	2010/11-2012/13 Average	2011/12-2013/14 Average	2012/13-2014/15 Average	2013/14-2015/16 Average	2010/11- 2015/16 Average
England		45.00	46.23	47.37	48.50	46.75
London NHS region						

## Rolling Averages Detection Rates Index Table

**Note: This table is not available at the London level**

Source: <http://fingertips.phe.org.uk/profile/cancerservices>

**Area:** London NHS region

Three-year rolling average detection rates have been presented at a practice level for a selected CCG, along with the average detection rate over the six years.

Low numbers of suspected cancer cases at a practice level can lead to large fluctuation in the detection rates. To account for this, three-year rolling averages have been calculated.

Practice Code	Practice Name	2010/11-2012/13 Average	2011/12-2013/14 Average	2012/13-2014/15 Average	2013/14-2015/16 Average	2010/11- 2015/16 Average
---------------	---------------	----------------------------	----------------------------	----------------------------	----------------------------	-----------------------------

## GP Practice Index Table

**Note: This table is not available at the London level**

Source: <http://fingertips.phe.org.uk/profile/cancerservices>

For further information regarding population size of each practice, and additional variables, for the most recent year please visit <http://fingertips.phe.org.uk/profile/general-practice/data>

Area:		London NHS region			
Practice Code	Practice Name	New cancer cases (rate per 100,000 population)	Quality and Outcomes Framework (QOF) Prevalence (%)	Proportion of population 65+ (%)	Practice specific deprivation score (IMD Score)
Most recent year available:		2013-14	2015-16	2016	2015
NHS Barking And Dagenham CCG		350.6	1.2	8.8	34.6
NHS Barnet CCG		393	2.1	13.8	17.8
NHS Bexley CCG		490.6	2.5	16.8	16.2
NHS Brent CCG		320.3	1.4	10.1	26.7
NHS Bromley CCG		464.6	2.5	17.5	15.2
NHS Camden CCG		292.5	1.7	9	25
NHS Central London (Westminster) CCG		320	1.7	10.2	25.7
NHS City And Hackney CCG		283.7	1.3	7.1	34.6
NHS Croydon CCG		372.1	1.9	12.7	23.6
NHS Ealing CCG		333.1	1.5	10.5	23.6
NHS Enfield CCG		386.8	1.9	12.8	27
NHS Greenwich CCG		351.2	1.6	10.3	25.5
NHS Hammersmith And Fulham CCG		339.2	1.6	9.4	24.4
NHS Haringey CCG		311.9	1.6	9.5	31
NHS Harrow CCG		369.5	1.9	14.2	14.3
NHS Havering CCG		563.1	2.3	18.1	17.9
NHS Hillingdon CCG		382.9	1.6	13.1	18.1
NHS Hounslow CCG		330.6	1.5	10.7	22.5
NHS Islington CCG		340.5	1.5	8.8	32.5
NHS Kingston CCG		373.7	1.9	12.7	11.1
NHS Lambeth CCG		302.3	1.4	7.6	28.9
NHS Lewisham CCG		327	1.5	9.4	28.6
NHS Merton CCG		419.6	1.8	11.9	14.9
NHS Newham CCG		212.4	0.9	6.5	32.9
NHS Redbridge CCG		326.4	1.4	11.8	20.2
NHS Richmond CCG		409.7	2.2	13.9	10
NHS Southwark CCG		275.5	1.4	7.8	29.5
NHS Sutton CCG		456.1	2.2	14.9	14.6
NHS Tower Hamlets CCG		225.2	0.9	5.7	35.7
NHS Waltham Forest CCG		345.7	1.4	9.7	30.2
NHS Wandsworth CCG		314.3	1.5	8.6	18.3
NHS West Essex CCG		537.3	2.4	17.6	16.1
NHS West London (K&C & QPP) CCG		361.7	1.8	11.5	26.1

## GP Practice Index Table

**Note: This table is not available at the London level**

Source: <http://fingertips.phe.org.uk/profile/cancerservices>

For further information regarding population size of each practice, and additional variables, for the most recent year please visit <http://fingertips.phe.org.uk/profile/general-practice/data>

Area:		London NHS region			
Practice Code	Practice Name	New cancer cases (rate per 100,000 population)	Quality and Outcomes Framework (QOF) Prevalence (%)	Proportion of population 65+ (%)	Practice specific deprivation score (IMD Score)
Most recent year available:		2013-14	2015-16	2016	2015